Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TNFSF10 | P50591 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP4 | P49662 | 1/20 | 0.35 |
| ▸ | CASP5 | P51878 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627866 | 0.92 | MEN1 (0.54) | MEN1KMT2AMTORMAPTALDH1A1 | |
| SCHEMBL3715528 | 0.88 | KMT2A (0.51) | MEN1KMT2AMTORMAPTHRH4 | |
| SCHEMBL7869710 | 0.86 | KMT2A (0.49) | MEN1KMT2AMTORMAPTALDH1A1 | |
| SCHEMBL628412 | 0.82 | MTOR (0.52) | MTORMAPTCYP1A2PIK3CAHTT | |
| SCHEMBL629777 | 0.82 | HRH4 (0.47) | MEN1KMT2AMAPTALDH1A1HRH4 | |
| SCHEMBL17527868 | 0.81 | MTOR (0.42) | MTORPIK3CA | |
| SCHEMBL628391 | 0.81 | KMT2A (0.47) | MEN1KMT2AMTORMAPTHRH4 | |
| SCHEMBL3721494 | 0.80 | KMT2A (0.74) | MEN1KMT2AMAPTALDH1A1CYP1A2 | |
| SCHEMBL629664 | 0.78 | MAP3K12 (0.47) | MEN1KMT2AMTORMAPTHRH4 | |
| SCHEMBL629287 | 0.77 | MEN1 (0.51) | MEN1KMT2AMAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419432-B9 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2419432-B1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2419432-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120998-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | MEN1 2335/4885KMT2A 2762/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.